Aytu BioScience

Aytu BioPharma, Inc., listed on NASDAQ under the ticker AYTU, operates as a specialty pharmaceutical company with a strategic focus on commercializing therapeutics for Attention Deficit Hyperactivity Disorder (ADHD) and pediatric conditions. The company was co-founded in 2015 by Chairman and CEO Josh Disbrow and his brother Jarrett Disbrow, who serves as EVP of Corporate Development. Josh Disbrow brings nearly twenty-five years of experience in the life sciences sector, having held leadership roles at several pharmaceutical and diagnostic companies, including Arbor Pharmaceuticals and Ampio Pharmaceuticals. His journey in the industry began as a sales representative at Glaxo Wellcome, and his extensive commercialization experience has been pivotal in Aytu's growth. The company went public on NASDAQ in 2017.

Aytu's business model is centered on acquiring or in-licensing FDA-approved products, thereby mitigating the risks associated with clinical development and focusing on commercial execution. Revenue is generated through the sale of its prescription pharmaceutical products. The company's portfolio has evolved through strategic acquisitions, including a merger with Neos Therapeutics in 2021, which significantly expanded its ADHD franchise and transformed Aytu into a company with revenues projected to exceed $100 million. Another key acquisition was Innovus Pharmaceuticals in 2020, which added a portfolio of over 35 consumer health products.

The company's primary products are prescription therapeutics for ADHD, including Adzenys XR-ODT and Cotempla XR-ODT, which are notable for being the only extended-release, orally disintegrating tablets for the condition. Its pediatric portfolio includes products like Karbinal® ER, Poly-Vi-Flor®, and Tri-Vi-Flor®. A key component of Aytu's commercial strategy is its proprietary A2RxConnect program. This patient access platform is designed to streamline the process for patients to receive their prescriptions at a predictable and affordable co-pay, guaranteeing that commercially insured patients pay no more than $50 for their medication.

Keywords: Aytu BioPharma, specialty pharmaceuticals, ADHD treatment, pediatric therapeutics, Josh Disbrow, commercialization, NASDAQ:AYTU, Adzenys XR-ODT, Cotempla XR-ODT, A2RxConnect, pharmaceutical acquisitions, CNS diseases, orally disintegrating tablets, prescription drugs, healthcare, life sciences, consumer health, pharmaceutical licensing, patient access programs